Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 patients from 12 studies.

Sebastiaan Ten Bokkel HuininkDoranne ThomassenEwout W SteyerbergRenske W M PauwelsMaria J CasanovaGuillaume BouguenJoyce W Y MakTamas MolnárAlan J LoboJacob B SeidelinAurélien AmiotGeert D'HaensPauline Riviere Luisa GuidiRenata BorWei-Chen LinLaurent Peyrin-BirouletFrancisco Javier García-AlonsoC Janneke van der WoudeAnnemarie C de Vries

Published in: Journal of Crohn's & colitis (2023)

This IPD-MA, on predominantly patients with pCD without active luminal disease and first line anti-TNF therapy, shows that over half of patients remain in remission 2 years after anti-TNF discontinuation. Therefore, anti-TNF discontinuation may be considered in this subgroup.

Keyphrases

rheumatoid arthritis
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
stem cells
disease activity
electronic health record
systemic lupus erythematosus
big data
bone marrow
mesenchymal stem cells
open label
data analysis
patient reported